Abstract
IntroductionSodium–glucose cotransporter 2 (SGLT2) inhibitors are now recommended in guidelines for persons with type 2 diabetes mellitus (T2DM) and at risk of advanced kidney disease as part of the glucose-lowering...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have